Immunohistochemical analysis of survivin expression in thyroid follicular adenoma and carcinoma

Applied Immunohistochemistry and Molecular Morphology

Volumn 14, Issue 4, 2006, Pages 422-425

  Haghpanah, Vahid ^a   Shooshtarizadeh, Peiman ^a   Heshmat, Ramin ^a   Larijani, Bagher ^a   Tavangar, Seyed Mohamad ^a,b  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Apoptosis; Follicular neoplasm; Survivin; Thyroid cancer

Indexed keywords

SURVIVIN;

ADULT; APOPTOSIS; ARTICLE; CANCER DIAGNOSIS; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; THYROID ADENOMA; THYROID FOLLICULAR ADENOMA; THYROID FOLLICULAR CARCINOMA;

ADENOCARCINOMA, FOLLICULAR; ADENOMA; ADULT; DIAGNOSIS, DIFFERENTIAL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MICROTUBULE-ASSOCIATED PROTEINS; MIDDLE AGED; NEOPLASM PROTEINS; PROSPECTIVE STUDIES; THYROID NEOPLASMS;

EID: 33751367171     PISSN: 15412016     EISSN: 15334058     Source Type: Journal    
DOI: 10.1097/01.pai.0000213100.88074.b8     Document Type: Article

References (29)

1. Mackenzie EJ, Mortimer RH. Thyroid nodules and thyroid cancer. Med J Aust. 2004;180:242-247.
2. Greaves TS, Olvera M, Florentine BD, et al. Follicular lesions of thyroid: a 5-year fine-needle aspiration experience. Cancer. 2000;906:335-341.
3. Baloch ZW, Fleisher S, LiVolsi VA, et al. Diagnosis of "follicular neoplasm": a gray zone in thyroid fine-needle aspiration cytology. Diagn. Cytopathol. 2002;26:41-44.
4. Goellner JR, Gharib H, Grant CS, et al. Fine needle aspiration cytology of the thyroid, 1980 to 1986. Acta Cytol. 1987;31:587-590.
5. Li F. Survivin study: what is the next wave? J Cell Physiol. 2003;197:8-29.
6. Altieri DC. The molecular basis and potential role of survivin in cancer diagnosis and therapy. Trends Mol Med. 2001;7:542-547.
7. Ambrosini G, Adida C, Altieri DC. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med. 1997;3:917-921.
8. Velculescu VE, Madden SL, Zhang L, et al. Analysis of human transcriptomes. Nat Genet. 1999;23:387-388.
9. O'Connor DS, Schechner JS, Adida C, et al. Control of apoptosis during angiogenesis by survivin expression in endothelial cells. Am J Pathol. 2000;156:393-398.
10. Ito Y, Yoshida H, Uruno T, et al. Survivin expression is significantly linked to the dedifferentiation of thyroid carcinoma. Oncol Rep. 2003;10:1337-1340.
11. Sarela AI, Macadam RC, Farmery SM, et al. Expression of the antiapoptosis gene, survivin, predicts death from recurrent colorectal carcinoma. Gut. 2000; 46:645-650.
12. Lin JD, Huang MJ, Juang JH, et al. Factors related to the survival of papillary and follicular thyroid carcinoma patients with distant metastases. Thyroid. 1999;9:1227-1235.
13. Chen KT, Lin JD, Chao TC, et al. Identifying differentially expressed genes associated with metastasis of follicular thyroid cancer by cDNA expression array. Thyroid. 2001;1:41-46.
14. Monzo M, Rosell R, Felip E, et al. A novel anti-apoptosis gene: re-expression of survivin messenger RNA as a prognosis marker in non-small-cell lung cancers. J Clin Oncol. 1999;17:2100-2104.
15. Tanaka K, Iwamoto S, Gon G, et al. Expression of survivin and its relationship to loss of apoptosis in breast carcinomas. Clin Cancer Res. 2000;6:127-134.
16. Kawasaki H, Altieri DC, Lu CD, et al. Inhibition of apoptosis by survivin predicts shorter survival rates in colorectal cancer. Cancer Res. 1998;58:5071-5074.
17. Lu CD, Altieri DC, Tanigawa N. Expression of a novel antiapoptosis gene, survivin, correlated with tumor cell apoptosis and p53 accumulation in gastric carcinomas. Cancer Res. 1998;58:1808-1812.
18. Kato J, Kuwabara Y, Mitani M, et al. Expression of survivin in esophageal cancer: correlation with the prognosis and response to chemotherapy. Int J Cancer. 2001;95:92-95.
19. Satoh K, Kaneko K, Hirota M, et al. Expression of survivin is correlated with cancer cell apoptosis and is involved in the development of human pancreatic duct cell tumors. Cancer. 2001;92:271-278.
20. Swana HS, Grossman D, Anthony JN, et al. Tumor content of the antiapoptosis molecule survivin and recurrence of bladder cancer. N Engl J Med. 1999;341:452-453.
21. Adida C, Berrebi D, Peuchmaur M, et al. Anti-apoptosis gene, survivin, and prognosis of neuroblastoma. Lancet. 1998;351:882-883.
22. Gasbarri A, Martegani MP, Del PF, et al. Galectin-3 and CD44v6 isoforms in the preoperative evaluation of thyroid nodules. J Clin Oncol. 1999;17:3494-3502.
23. Orlandi F, Saggiorato E, Pivano G, et al. Galectin-3 is a presurgical marker of human thyroid carcinoma. Cancer Res. 1998;58:3015-3020.
24. Coli A, Bigotti G, Zucchetti F, et al. Galectin-3, a marker of well-differentiated thyroid carcinoma, is expressed in thyroid nodules with cytological atypia. Histopathology. 2002;40:80-87.
25. Schlinkert RT, van Heerden JA, Goellner JR, et al. Factors that predict malignant thyroid lesions when fine-needle aspiration is "suspicious for follicular neoplasm". Mayo Clin Proc. 1997;72:913-916.
26. Tuttle RM, Lemar H, Burch HB. Clinical features associated with an increased risk of thyroid malignancy in patients with follicular neoplasia by fine-needle aspiration. Thyroid. 1998;8:377-383.
27. Bartolazzi A. Improving accuracy of cytology for nodular thyroid lesions. Lancet. 2000;355:1661-1662.
28. Segev DL, Umbricht C, Zeiger MA. Molecular pathogenesis of thyroid cancer. Surg Oncol. 2003;12:69-90.
29. Stojadinovic A, Ghossein RA, Hoos A, et al. Hurthle cell carcinoma: a critical histopathologic appraisal. J Clin Oncol. 2001;19:2616-2625.